Featured Research

from universities, journals, and other organizations

Cancer Stem Cells Similar To Normal Stem Cells Can Thwart Anti-cancer Agents

Date:
June 17, 2007
Source:
University of Pittsburgh Schools of the Health Sciences
Summary:
Current cancer therapies often are thwarted because they cannot eliminate a small reservoir of multiple-drug-resistant tumor cells. Researchers suggest that for chemotherapy to be truly effective in treating lung cancers, for example, it must be able to target a small subset of cancer stem cells, which they have shown share the same protective mechanisms as normal lung stem cells.

Current cancer therapies often succeed at initially eliminating the bulk of the disease, including all rapidly proliferating cells, but are eventually thwarted because they cannot eliminate a small reservoir of multiple-drug-resistant tumor cells, called cancer stem cells, which ultimately become the source of disease recurrence and eventual metastasis.

Now, research by scientists at the University of Pittsburgh School of Medicine suggests that for chemotherapy to be truly effective in treating lung cancers, for example, it must be able to target a small subset of cancer stem cells, which they have shown share the same protective mechanisms as normal lung stem cells.

The University of Pittsburgh researchers, led by Vera Donnenberg, Ph.D., assistant professor of surgery and pharmaceutical sciences, University of Pittsburgh Schools of Medicine and Pharmacy, used cell surface markers and dyes to identify cancer stem cells as well as normal adult stem cells and their progeny in samples obtained from normal lung and lung cancer tissue samples. The researchers identified a very small, rare set of resting cancer stem cells in the lung cancer samples that looked and behaved much like normal adult lung tissue stem cells. Both the cancer and normal stem cells were protected equally by multiple drug resistance transporters, even if the bulk of the tumor responded to chemotherapy.

According to Dr. Donnenberg, the very fact that cancers can and do relapse after apparently successful therapy indicates the survival of a drug-resistant, tumor-initiating population of cells in many types of refractory cancers. "Because of the similarities between the way that normal stem cells and cancer stem cells protect themselves, cancer therapies have to be designed specifically to target cancer stem cells while sparing normal stem cells," she explained.

Researchers are presenting this study at the Tissue Engineering and Regenerative Medicine International Society (TERMIS) North American Chapter meeting being held June 13 to 16 at the Westin Harbor Castle conference center in Toronto.

In addition to Dr. Donnenberg, others involved in this study included Rodney J. Landreneau, M.D., department of surgery, and Albert D. Donnenberg, Ph.D., department of medicine, University of Pittsburgh School of Medicine.


Story Source:

The above story is based on materials provided by University of Pittsburgh Schools of the Health Sciences. Note: Materials may be edited for content and length.


Cite This Page:

University of Pittsburgh Schools of the Health Sciences. "Cancer Stem Cells Similar To Normal Stem Cells Can Thwart Anti-cancer Agents." ScienceDaily. ScienceDaily, 17 June 2007. <www.sciencedaily.com/releases/2007/06/070615110244.htm>.
University of Pittsburgh Schools of the Health Sciences. (2007, June 17). Cancer Stem Cells Similar To Normal Stem Cells Can Thwart Anti-cancer Agents. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2007/06/070615110244.htm
University of Pittsburgh Schools of the Health Sciences. "Cancer Stem Cells Similar To Normal Stem Cells Can Thwart Anti-cancer Agents." ScienceDaily. www.sciencedaily.com/releases/2007/06/070615110244.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins